Clinical Trial Update: Single-Dose Islatravir in Moderate Hepatic Impairment (MK-8591-030) [Phase 1]

View source ↗

Summary

Phase 1 MK-8591-030 reports results for a single-dose islatravir in individuals with moderate hepatic impairment; the study is completed and results were posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Islatravir (Islatravir)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Human Immunodeficiency Virus (HIV) Infection | Phase 1 | Status: COMPLETED | Results posted: 2023-07-03